SCHEMBL15907666

SCHEMBL15907666

Cc1cnc2c(c1)cc(Br)n2S(=O)(=O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 2/20 0.45
LMNA P02545 2/20 0.39
ALDH3A1 P30838 2/20 0.38
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
CYP1A2 P05177 1/20 0.37
BRD4 O60885 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
GAA P10253 3/20 0.37
NOD1 Q9Y239 3/20 0.37
CXCL8 P10145 2/20 0.37
NOD2 Q9HC29 1/20 0.36
ENPP3 O14638 1/20 0.36
ENPP1 P22413 1/20 0.36
CYP2C19 P33261 1/20 0.36
SRC P12931 1/20 0.35
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15907696 0.84 SLC40A1 (0.45) SLC40A1LMNAALDH3A1PPARGPPARA
SCHEMBL7515939 0.80 ENPP3 (0.50) SLC40A1LMNABRD4PTGDR2GAA
SCHEMBL2590156 0.79 CYP2C19 (0.55) SLC40A1LMNAPTGDR2NOD1CXCL8
SCHEMBL26969492 0.77 ALDH3A1 (0.44) SLC40A1LMNAALDH3A1PTGDR2GAA
SCHEMBL15907693 0.76 SLC40A1 (0.39) SLC40A1LMNAPPARGPPARAPTGDR2
SCHEMBL15907679 0.76 SLC40A1 (0.39) SLC40A1ALDH3A1PPARGPPARABRD4
SCHEMBL13575362 0.76 L3MBTL1 (0.58) SLC40A1LMNAALDH3A1PTGDR2GAA
SCHEMBL1958833 0.75 CYP2C19 (0.61) SLC40A1LMNABRD4CYP2C19POLB
SCHEMBL15819107 0.74 F2 (0.37) LMNAPPARGPPARAPTGDR2ENPP3
SCHEMBL15818931 0.74 RORC (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170349572-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2017-12-07 US disclosed
US-9676748-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2017-06-13 US disclosed
US-20140213554-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213554-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, PRKCH, PRKACA SLC40A1 4165/4885LMNA 1253/4885ALDH3A1 1826/4885
US-20170349572-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, PRKCH, PRKACA SLC40A1 4165/4885LMNA 1253/4885ALDH3A1 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.